Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy of HIV1 infection: Case report

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Parruti, Guistino ^a,b   Toro, Giuseppe Marani ^a  

^a Ospedle Civile Spirito Santo   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADIPOSE TISSUE; ADULT; ARTICLE; BREAST; CASE REPORT; DRUG WITHDRAWAL; FACE DEFORMITY; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID STORAGE; LIPOATROPHY; LUMBAR SPINE; LYMPHOCYTE COUNT; NEPHROLITHIASIS; TREATMENT PLANNING; VIREMIA; VIRUS INHIBITION; WAIST CIRCUMFERENCE; CHEMICALLY INDUCED DISORDER; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; TIME FACTORS;

EID: 27644455778     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-80     Document Type: Article

References (17)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-9.
3. Carr A: HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003, Suppl 1:141-148.
4. Tershakovec AM, Frank I, Rader D: HIV-related lipodystrophy and related factors. Atherosclerosis 2004, 174:1-10.
5. Koutkia P, Grinspoon S: HIV-Associated lipodystrophy: Pathogenesis, Prognosis, Treatment, and Controversies. Annu Rev Med 2004, 55:303-17.
6. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, Rhodes PH, Wood KC, Holmberg SD: Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001, 15:1389-1398.
7. Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, Basdevant A, Leport C, Chene G: Factors Related to Lipodystrophy and Metabolic Alterations in Patients with Human Immunodeficiency Virus Infection Receiving Highly Active Antiretroviral Therapy. Clin Infect Dis 2002, 34:1396-405.
8. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, Yeni P: Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002, 16:2447-2454.
9. Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, Moroni M: Correlates of risk of adipose tissue alterations and their modification over time in HIV-1 infected women treated with antiretroviral therapy. Antiviral Therapy 2003, 8:347-354.
10. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002, 288:207-215.
11. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG: A 48-Week, Randomized, Open-Label Comparison of Three Abacavir-Based Substitution Approaches in the Management of Dyslipidemia and Peripheral Lipoatrophy. JAIDS 2003, 33:22-28.
12. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N, Freund J, Cooper DA: Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004, 18:1029-1036.
13. Mussini C, Bugarini R, Perno CF, Antinori A, Borghi V, Bertoli A, D'Arrigo R, Bedini A, Mongiardo N, Cossarizza A, Esposito R: Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells /microl. AIDS 2002, 16:1551-1553.
14. Boschi A, Tinelli C, Ortolani P, Moscatelli G, Morigi G, Arlotti M: CD4+ cell count guided treatment interruptions in chronic HIV-infected patients with good response to HAART. AIDS 2004, 18:2381-2389.
15. Roche R, Poizot-Martin I, El Yazidi CM, Compe E, Gastaut JA, Torresani J, Planells R: Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 2002, 16:13-20.
16. Blanch J, Rousaud A, Martínez E, De Lazzari E, Milinkovic A, Peri JM, Blanco JL, Jaen J, Navarro V, Massana G, Gatell JM: Factors Associated with Severe Impact of Lipodystrophy on the Quality of Life of Patients Infected with HIV-1. Clin Infect Dis 2004, 38:1464-1470.
17. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK: 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191-201.